365 related articles for article (PubMed ID: 11055896)
21. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
Tavormina PL; Shiang R; Thompson LM; Zhu YZ; Wilkin DJ; Lachman RS; Wilcox WR; Rimoin DL; Cohn DH; Wasmuth JJ
Nat Genet; 1995 Mar; 9(3):321-8. PubMed ID: 7773297
[TBL] [Abstract][Full Text] [Related]
22. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling.
Lievens PM; Mutinelli C; Baynes D; Liboi E
J Biol Chem; 2004 Oct; 279(41):43254-60. PubMed ID: 15292251
[TBL] [Abstract][Full Text] [Related]
23. Genotype and phenotype in hypochondroplasia.
Ramaswami U; Rumsby G; Hindmarsh PC; Brook CG
J Pediatr; 1998 Jul; 133(1):99-102. PubMed ID: 9672519
[TBL] [Abstract][Full Text] [Related]
24. Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.
Couser NL; Pande CK; Turcott CM; Spector EB; Aylsworth AS; Powell CM
Am J Med Genet A; 2017 Apr; 173(4):1097-1101. PubMed ID: 28181399
[TBL] [Abstract][Full Text] [Related]
25. Mouse models orthologous to FGFR3-related skeletal dysplasias.
Brodie SG; Deng CX
Pediatr Pathol Mol Med; 2003; 22(1):87-103. PubMed ID: 12687892
[TBL] [Abstract][Full Text] [Related]
26. Prenatal and postnatal presentation of severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) due to the FGFR3 Lys650Met mutation.
Zankl A; Elakis G; Susman RD; Inglis G; Gardener G; Buckley MF; Roscioli T
Am J Med Genet A; 2008 Jan; 146A(2):212-8. PubMed ID: 18076102
[TBL] [Abstract][Full Text] [Related]
27. G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia.
Katsumata N; Kuno T; Miyazaki S; Mikami S; Nagashima-Miyokawa A; Nimura A; Horikawa R; Tanaka T
Endocr J; 1998 Apr; 45 Suppl():S171-4. PubMed ID: 9790257
[TBL] [Abstract][Full Text] [Related]
28. Common mutations in the gene encoding fibroblast growth factor receptor 3 account for achondroplasia, hypochondroplasia and thanatophoric dysplasia.
Bonaventure J; Rousseau F; Legeai-Mallet L; Le Merrer M; Munnich A; Maroteaux P
Acta Paediatr Suppl; 1996 Oct; 417():33-8. PubMed ID: 9055906
[TBL] [Abstract][Full Text] [Related]
29. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
30. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism.
Bonaventure J; Rousseau F; Legeai-Mallet L; Le Merrer M; Munnich A; Maroteaux P
Am J Med Genet; 1996 May; 63(1):148-54. PubMed ID: 8723101
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.
Meyers GA; Orlow SJ; Munro IR; Przylepa KA; Jabs EW
Nat Genet; 1995 Dec; 11(4):462-4. PubMed ID: 7493034
[TBL] [Abstract][Full Text] [Related]
32. [Mutations in the Fibroblast Growth Factor Receptor 3 gene (FGFR3) in Chilean patients with idiopathic short stature, hypochondroplasia and achondroplasia].
Mancilla EE; Poggi H; Repetto G; García C; Foradori A; Cattani A
Rev Med Chil; 2003 Dec; 131(12):1405-10. PubMed ID: 15022403
[TBL] [Abstract][Full Text] [Related]
33. Thanatophoric dysplasia caused by double missense FGFR3 mutations.
Pannier S; Martinovic J; Heuertz S; Delezoide AL; Munnich A; Schibler L; Serre V; Legeai-Mallet L
Am J Med Genet A; 2009 Jun; 149A(6):1296-301. PubMed ID: 19449430
[TBL] [Abstract][Full Text] [Related]
34. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
35. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
[TBL] [Abstract][Full Text] [Related]
36. A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia.
Winterpacht A; Hilbert K; Stelzer C; Schweikardt T; Decker H; Segerer H; Spranger J; Zabel B
Physiol Genomics; 2000 Jan; 2(1):9-12. PubMed ID: 11015576
[TBL] [Abstract][Full Text] [Related]
37. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
Webster MK; Donoghue DJ
EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
[TBL] [Abstract][Full Text] [Related]
38. p.Ser348Cys mutation in FGFR3 gene leads to "Mild ACH /Severe HCH" phenotype.
Bengur FB; Ekmekci CG; Karaarslan E; Gunoz H; Alanay Y
Eur J Med Genet; 2020 Feb; 63(2):103659. PubMed ID: 31048079
[TBL] [Abstract][Full Text] [Related]
39. Hypochondroplasia in a child with 1620C>G (Asn540Lys) mutation in FGFR3.
Korkmaz HA; Hazan F; Dizdarer C; Tükün A
J Clin Res Pediatr Endocrinol; 2012 Dec; 4(4):220-2. PubMed ID: 23149434
[TBL] [Abstract][Full Text] [Related]
40. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
Tsai FJ; Tsai CH; Chang JG; Wu JY
Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
